Ribosome profiling in mouse hippocampus: plasticity-induced regulation and bidirectional control by TSC2 and FMRP.
Annie Hien, Gemma Molinaro, Botao Liu and 2 others
PMID 33054857WHAT IT FOUND
Mouse hippocampal slices showed that a low dose of a protein synthesis inhibitor restored synaptic plasticity in TSC models.
This mechanism relies on ribosome elongation, not the mTOR pathway. The finding is preclinical and has no current application for human therapy.
Key findings
01In Tsc2 mutant mice, the mGluR-LTD deficit was enhanced by low-dose cycloheximide, a translation elongation inhibitor.
02Tsc2 mutant slices failed to increase phospho-eEF2 levels after DHPG stimulation, unlike wild-type slices.
03Ribosome profiling revealed that FMRP binding targets have increased RNA levels but decreased translational efficiency in Tsc2 mutant mice.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study is entirely preclinical, using mouse hippocampal slices; it does not involve human participants or clinical outcomes. Sequencing analysis had low statistical power (n=3 biological replicates), increasing the risk of false negatives. The use of pooled samples from multiple mice for sequencing limits the ability to detect individual variation. Changes in ribosome density (RPF) may not directly reflect changes in protein synthesis rates due to potential ribosome stalling. The mechanism involves specific molecular pathways (eEF2, FMRP) that are not currently targets for therapy in Tuberous Sclerosis Complex patients.
Declared interests
Funding was provided by the Simons Foundation, National Institute of General Medical Sciences, and National Institute of Child Health and Human Development. No commercial conflicts of interest were declared.
The easy way to misread this
Do not interpret the restoration of synaptic plasticity by cycloheximide in mouse slices as a potential treatment for Tuberous Sclerosis. Cycloheximide is a toxic protein synthesis inhibitor unsuitable for human use, and the study provides no evidence of efficacy or safety in patients.